Андрология и генитальная хирургия. 2015; 16: 61-65
Патогенетическое обоснование биологически активной добавки ТестогенонТМ для комплексного воздействия на мужскую репродуктивную систему
https://doi.org/10.17650/2070-9781-2015-16-2-61-65Аннотация
Создан патогенетически обоснованный комплексный препарат ТестогенонТМ для профилактики и лечения расстройств репродуктивной системы мужчин, включающий экстракты растений (коры пиджеума, диоскореи, йохимбе, корня женьшеня) и биологически активные вещества (L-аргинин, витамины С, Е, В5, В6 и В12). Безвредность и безопасность препарата подтверждены в экспериментальных исследованиях. Доклинические исследования специфической фармакологической активности биологически активной добавки к пище ТестогенонТМ позволили установить стимуляцию у экспериментальных животных выработки собственного тестостерона, концентрация которого была достоверно выше, чем у контрольных животных. Кроме того, у крыс, получавших ТестогенонТМ, наблюдалась активация всех показателей полового поведения. Средняя частота садок на самок была выше на 82 %, а количество интромиссий больше в 12–15 раз, чем у контрольных животных, также достоверно снижался латентный период садок и интервал между сессиями.
Препарат рекомендуется для усиления либидо, увеличения продолжительности полового акта, устранения эректильной дисфункции, облегчения возрастных проявлений мужского климакса, а также в рамках комплексной терапии доброкачественной гиперплазии предстательной железы, хронического небактериального простатита, мужского бесплодия, недержания мочи, стимуляции синтеза тестостерона. ТестогенонТМ противопоказан при повышенной нервной возбудимости, бессоннице, артериальной гипертензии, снижении свертываемости крови, аритмии, выраженных нарушениях функции печени и почек.
Список литературы
1. Пушкарь Д.Ю., Камалов А.А., АльШукри С.Х. и др. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Русский медицинский журнал 2012;3:112–5. [Pushkar D.Yu., Kamalov А.А., Al-Shukri S.H. et al. Epidemiologic study of erectile dysfunction distribution in the Russian Federation. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2012;3:112–5. (In Russ.)].
2. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А. и др. Комбинированное лечение больных эректильной дисфункцией, страдающих расстройствами мочеиспускания. Урология 2013;3:29–33. [Kamalov A.A., Osmolovsky B.E., Okhobotov D.A. et al. Combined management of patients with erectile dysfunction, suffering from urinary disorders. Urologiya = Urology 2013;3:29–33. (In Russ.)].
3. Handbook of urology. 1st ed. J.K. Parsons, J.B. Eifler, M. Han (eds.). West Sussex: John Wiley & Sons, 2014. 312 p.
4. Урология: национальное руководство. Н.А. Лопаткин (ред.) М.: ГЭОТАР-Медиа, 2009. 1024 с. [Urology: National Guideline. N.A. Lopatkin (ed.). Moscow: GEOTAR-Media, 2009. 1024 p. (In Russ.)].
5. Бабанов С.А., Косарева О.В., Воробьева Е.В., Бараева Р.А. Оценка выраженности эректильной дисфункции и андрогенного дефицита у мужчин при вибрационной болезни. Русский медицинский журнал 2014;27:1978–9. [Babanov S.A., Kosareva O.V., Vorobyeva E.V., Baraeva R.A. Erectile dysfunction and androgen deficiency severity assessment in men at vibration disease. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2014;27:1978–9. (In Russ.)].
6. Jensen T.K., Gottschau M., Madsen J.O. et al. Habitual alcohol consumption associated with reduced semen quality and changes in reproductive hormones; a crosssectional study among 1221 young Danish men. BMJ Open 2014;4(9):1–9.
7. Jensen T.K., Swan S., Jørgensen N. et al. Alcohol and male reproductive health: a cross-sectional study of 8344 healthy men from Europe and the USA. Hum Reprod 2014;29(8):1801–9.
8. Макарова М.Н., Макаров В.Г. Молекулярная биология флавоноидов (химия, биохимия, фармакология): Руководство для врачей. СПб., 2010. 428 с. [Makarova M.N., Makarov V.G. Molecular biology of flavonoids (chemistry, biochemistry, pharmacology): Guideline for physicians. Saint Petersburg, 2010. 428 p. (In Russ.)].
9. Clarke D.B., Barnes K.A., Lloyd A.S. Determination of unusual soya and non-soya phytoestrogen sources in beer, fish products and other foods. Food Addit Contam 2004;21(10):949–62.
10. Zanoli P., Zavatti M. Pharmacognostic and pharmacological of Humulus lupulus L. J Ethnopharmacol 2008;166(3):383–96.
11. Yuan Y., Qiu X., Nikolić D. et al. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci 2014;53:55–61.
12. Possemiers S., Rabot S., Espín J.C. et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr 2008;138(7):1310–6.
13. Possemiers S., Verstraete W. Oestrogenicity of prenylflavonoids from hops: activation of pro-oestrogens by intestinal bacteria. Environ Microbiol Rep 2009;1(2):100–9.
14. Wisniewski A.B., Klein S.L., Lakshmanan Y., Gearhart J.P. Exposure to genistein during gestation and lactation demasculinizes the reproductive system in rats. J Urol 2003;169(4):1582–6.
15. Akingbemi B.T., Braden T.D., Kemppainen B.W. et al. Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular leydig cells in the adult rat. Endocrinology 2007;148(9):4476–88.
16. Коган М.И., Белоусов И.И., Шангичев А.В. Играет ли дислипидемия патогенетическую роль в развитии невоспалительной формы хронического простатита/синдрома хронической тазовой боли? Урология 2012;5:46–52. [Kogan M.I., Belousov I.I., Shangichev A.V. Does the dislipidemy play the pathogenic role in development of noninflammatory form of chronic prostatitis/chronic pelvic pain syndrome? Urologiya = Urology 2012;5: 46–52. (In Russ.)].
17. Understanding pathophysiology. 5th ed. S.E. Huether, K.L. McCance (eds.). St. Louis, Missouri, 2012. 1187 р.
18. Тиктинский О.Л., Михайличенко В.В. Андрология. СПб.: Медиа Пресс, 1999. 464 с. [Tiktinsky O.L., Mikhailichenko V.V. Andrology. Saint Petersburg: Media Press, 1999. 464 p. (In Russ.)].
19. Suzuki H., Nakada T. Alteration of collagen biosynthesis and analysis of type I and type III collagens of prostate in young rats following sex hormone treatments. Arch Androl 1996;36(3):205–16.
20. Попов С.В. Применение Трибестана в лечении андрологических заболеваний. Русский медицинский журнал 2011;16:1013–7. [Popov S.V. Administration of Tribestan in management of andrological diseases. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2011;16:1013–7. (In Russ.)].
21. Каприн А.Д., Костин А.А., Виноградов И.В., Магамадов Э.Л. Лечение возрастного андрогенного дефицита у пациентов с доброкачественной гиперплазией предстательной железы. Урология 2015;1:79–82. [Kaprin A.D., Kostin A.A., Vinogradov I.V., Magamadov E.L. Management of androgen deficiency in aging male patients with benign prostatic hyperplasia. Urologiya = Urology 2015;1:79–82. (In Russ.)].
22. McKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev 2004;9(1):4–16.
23. McNicholas T., Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid 2011.
24. Нашивочникова Н.А., Крупин В.Н., Селиванова С.А. Эффективность спематона при мужском бесплодии. Урология 2014;2:52–4. [Nashivochnikova N.A., Krupin V.N., Selivanova S.A. Efficacy of Spematon administered at male infertility. Urologiya = Urology 2014;2:52–4. (In Russ.)].
25. Пульбере С.А., Авдошин В.П. Комбинированная терапия больных острым простатитом с применением фитопрепарата простагут форте. Урология 2012;5:57–63. [Pulbere S.A., Avdoshin V.P. Combined therapy of patients with acute prostatitis with administration of herb medicinal product Prostagutt forte. Urologiya = Urology 2012;5:57–63. (In Russ.)].
26. Лифляндский В.Г. Новейшая энциклопедия незаменимых веществ. СПб.: Нева, 2004. 384 с. [Liflyandsky V.G. The modern encyclopedia of essential nutrients. Saint Petersburg: Neva, 2004. 384 p. (In Russ.)].
27. Wilt T., Ishani A., Mac Donald R. et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;1.
28. Larré S., Camparo P., Comperat E. et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl 2012;14(3):499–504.
29. Allkanjari O., Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 2015;126:42–56.
30. Мазнев Н.И. Энциклопедия лекарственных растений. 3-е изд., испр. и доп. М.: Мартин, 2004. 496 с. [Maznev N.I. Encyclopedia of drug plants. 3rd revised and enlarged edition. Moscow: Martin, 2004. 496 p. (In Russ.)].
31. Виноградова Т.А., Гажёв Б.Н., Виноградов В.М., Мартынов В.К. Практическая фитотерапия М.: ОЛМА-ПРЕСС; СПб.: Нева, Валери СПД, 1998. 640 с. [Vinogradova T.A., Gazhyov B.N., Vinogradov V.M., Martynov V.K. Practical herbal medicine Moscow: OLMA-PRESS; Saint Petersburg: Neva, Valeri SPD, 1998. 640 p. (In Russ.)].
32. Корсун В.Ф., Корсун Е.В. Фитотерапия: традиции российского травничества. М.: Эксмо, 2010. 880 с. [Korsun V.F., Korsun E.V. Herbal Medicine: traditions of the russian herbal drugs. M: Eksmo, 2010. 880 p. (In Russ.)].
33. Jang D.J., Lee M.S., Shin B.C. et al. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol 2008;66(4):444–50.
34. Лифляндский В.Г. Витамины и минералы. М.: ЗАО «ОЛМА Медиа Групп», 2010. 640 с. [Liflyandsky V.G. Vitamins and minerals. Moscow: OLMA Media Group JSC, 2010. 640 p. (In Russ.)].
35. Encyclopedia of human nutrition. 2nd ed. B. Caballero, L. Allen, A. Prentice (eds.). Oxford, 2005. 2167 p.
36. Present knowledge in nutrition. 10th ed. J.W. Erdman Jr. , I.A. Macdonald, S.H. Zeisel (eds.). Ames (USA), Oxford (UK): International Life Sciences Institute, 2012. 1329 p.
37. Тутельян В.А., Вялков А.И., Разумов А.Н. и др. Научные основы здорового питания. М.: Панорама, 2010. 816 с. [V.A. Tutelyan, A.I. Vyalkov, A.N. Razumov et al. Scientific basis of healthy meal. Moscow: Panorama, 2010. 816 p. (In Russ.)].
38. Gropper S.S., Smith J.L. Advanced nutrition and human metabolism, 6th ed. Wadsworth, 2013. 608 p.
39. Whitney E., Rolfes S.R. Understanding Nutrition. 13th ed. Wadsworth, 2013. 975 p.
40. Доклиническое изучение острой и субхронической токсичности биологически активной добавки (БАД) к пище «ТестогенонТМ», капсулы, 0,5 г, производства ООО «ВИС». Отчет ФГБУ «Институт токсикологии ФМБА». Спб., 2012. 29 с. [Preclinical study of acute and subchronic toxicity of dietary supplement (DS) TestogenonTM, capsules, 0,5 g, manufactured by “VIS” LLC. Report of FSBI “Institute of Toxicology of Federal Medical and Biological Agency of Russia”. Saint Petersburg, 2012. 29 p. (In Russ.)].
41. Доклиническое изучение специфической фармакологической активности биологически активной добавки (БАД) к пище «ТестогенонТМ», капсулы, 0,5 г, производства ООО «ВИС». Отчет ФГБУ «Институт токсикологии ФМБА». Спб., 2012. 15 с. [Preclinical study of specific pharmacological activity of dietary supplement (DS) TestogenonTM, capsules, 0,5 g, manufactured by “VIS” LLC. Report of FSBI “Institute of Toxicology of Federal Medical and Biological Agency of Russia”. Saint Petersburg, 2012. 15 p. (In Russ.)].
Andrology and Genital Surgery. 2015; 16: 61-65
Pathogenetic justification of dietary supplement TestogenonTM for complex impact on men's reproductive system
https://doi.org/10.17650/2070-9781-2015-16-2-61-65Abstract
The reasonable complex preparation TestogenonTM for prevention and treatment of frustration of reproductive system of men including extracts of plants (bark of a pidzheum, a dioskorea, a yokhimba, a ginseng root) and biologically active agents (L-arginin, vitamins C and E, B5, B6 and B12) is created pathogenetic. Harmlessness and safety of a preparation are confirmed in pilot studies. Preclinical researches of specific pharmacological activity of dietary supplement to food TestogenonTM, allowed to establish stimulation at experimental animals of production of own testosterone which concentration was authentically above, than at control animals. Besides, at the rats receiving TestogenonTM activation of all indicators of sexual behavior was observed: average frequency a cage on females was 82 % higher, the quantity of intromissiya exceeded that control animals at 12–15 times, the latent period a cage and an interval between sessions authentically decreased.
The preparation is recommended for strengthening of a libido, increase in duration of sexual intercourse, elimination of erektilny dysfunction, simplification of age manifestations of a man's climax), and also within complex therapy of a good-quality hyperplasiya of a prostate gland, chronic not bacterial prostatitis, man's infertility, an incontience of urine, testosterone synthesis stimulation. TestogenonTM is contraindicated at the increased nervous excitability, sleeplessness, arterial hypertension, decrease in coagulability of blood, arrhythmia, the expressed dysfunction of a liver and kidneys.
References
1. Pushkar' D.Yu., Kamalov A.A., Al'Shukri S.Kh. i dr. Epidemiologicheskoe issledovanie rasprostranennosti erektil'noĭ disfunktsii v Rossiĭskoĭ Federatsii. Russkiĭ meditsinskiĭ zhurnal 2012;3:112–5. [Pushkar D.Yu., Kamalov A.A., Al-Shukri S.H. et al. Epidemiologic study of erectile dysfunction distribution in the Russian Federation. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2012;3:112–5. (In Russ.)].
2. Kamalov A.A., Osmolovskiĭ B.E., Okhobotov D.A. i dr. Kombinirovannoe lechenie bol'nykh erektil'noĭ disfunktsieĭ, stradayushchikh rasstroĭstvami mocheispuskaniya. Urologiya 2013;3:29–33. [Kamalov A.A., Osmolovsky B.E., Okhobotov D.A. et al. Combined management of patients with erectile dysfunction, suffering from urinary disorders. Urologiya = Urology 2013;3:29–33. (In Russ.)].
3. Handbook of urology. 1st ed. J.K. Parsons, J.B. Eifler, M. Han (eds.). West Sussex: John Wiley & Sons, 2014. 312 p.
4. Urologiya: natsional'noe rukovodstvo. N.A. Lopatkin (red.) M.: GEOTAR-Media, 2009. 1024 s. [Urology: National Guideline. N.A. Lopatkin (ed.). Moscow: GEOTAR-Media, 2009. 1024 p. (In Russ.)].
5. Babanov S.A., Kosareva O.V., Vorob'eva E.V., Baraeva R.A. Otsenka vyrazhennosti erektil'noĭ disfunktsii i androgennogo defitsita u muzhchin pri vibratsionnoĭ bolezni. Russkiĭ meditsinskiĭ zhurnal 2014;27:1978–9. [Babanov S.A., Kosareva O.V., Vorobyeva E.V., Baraeva R.A. Erectile dysfunction and androgen deficiency severity assessment in men at vibration disease. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2014;27:1978–9. (In Russ.)].
6. Jensen T.K., Gottschau M., Madsen J.O. et al. Habitual alcohol consumption associated with reduced semen quality and changes in reproductive hormones; a crosssectional study among 1221 young Danish men. BMJ Open 2014;4(9):1–9.
7. Jensen T.K., Swan S., Jørgensen N. et al. Alcohol and male reproductive health: a cross-sectional study of 8344 healthy men from Europe and the USA. Hum Reprod 2014;29(8):1801–9.
8. Makarova M.N., Makarov V.G. Molekulyarnaya biologiya flavonoidov (khimiya, biokhimiya, farmakologiya): Rukovodstvo dlya vracheĭ. SPb., 2010. 428 s. [Makarova M.N., Makarov V.G. Molecular biology of flavonoids (chemistry, biochemistry, pharmacology): Guideline for physicians. Saint Petersburg, 2010. 428 p. (In Russ.)].
9. Clarke D.B., Barnes K.A., Lloyd A.S. Determination of unusual soya and non-soya phytoestrogen sources in beer, fish products and other foods. Food Addit Contam 2004;21(10):949–62.
10. Zanoli P., Zavatti M. Pharmacognostic and pharmacological of Humulus lupulus L. J Ethnopharmacol 2008;166(3):383–96.
11. Yuan Y., Qiu X., Nikolić D. et al. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci 2014;53:55–61.
12. Possemiers S., Rabot S., Espín J.C. et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr 2008;138(7):1310–6.
13. Possemiers S., Verstraete W. Oestrogenicity of prenylflavonoids from hops: activation of pro-oestrogens by intestinal bacteria. Environ Microbiol Rep 2009;1(2):100–9.
14. Wisniewski A.B., Klein S.L., Lakshmanan Y., Gearhart J.P. Exposure to genistein during gestation and lactation demasculinizes the reproductive system in rats. J Urol 2003;169(4):1582–6.
15. Akingbemi B.T., Braden T.D., Kemppainen B.W. et al. Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular leydig cells in the adult rat. Endocrinology 2007;148(9):4476–88.
16. Kogan M.I., Belousov I.I., Shangichev A.V. Igraet li dislipidemiya patogeneticheskuyu rol' v razvitii nevospalitel'noĭ formy khronicheskogo prostatita/sindroma khronicheskoĭ tazovoĭ boli? Urologiya 2012;5:46–52. [Kogan M.I., Belousov I.I., Shangichev A.V. Does the dislipidemy play the pathogenic role in development of noninflammatory form of chronic prostatitis/chronic pelvic pain syndrome? Urologiya = Urology 2012;5: 46–52. (In Russ.)].
17. Understanding pathophysiology. 5th ed. S.E. Huether, K.L. McCance (eds.). St. Louis, Missouri, 2012. 1187 r.
18. Tiktinskiĭ O.L., Mikhaĭlichenko V.V. Andrologiya. SPb.: Media Press, 1999. 464 s. [Tiktinsky O.L., Mikhailichenko V.V. Andrology. Saint Petersburg: Media Press, 1999. 464 p. (In Russ.)].
19. Suzuki H., Nakada T. Alteration of collagen biosynthesis and analysis of type I and type III collagens of prostate in young rats following sex hormone treatments. Arch Androl 1996;36(3):205–16.
20. Popov S.V. Primenenie Tribestana v lechenii andrologicheskikh zabolevaniĭ. Russkiĭ meditsinskiĭ zhurnal 2011;16:1013–7. [Popov S.V. Administration of Tribestan in management of andrological diseases. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2011;16:1013–7. (In Russ.)].
21. Kaprin A.D., Kostin A.A., Vinogradov I.V., Magamadov E.L. Lechenie vozrastnogo androgennogo defitsita u patsientov s dobrokachestvennoĭ giperplazieĭ predstatel'noĭ zhelezy. Urologiya 2015;1:79–82. [Kaprin A.D., Kostin A.A., Vinogradov I.V., Magamadov E.L. Management of androgen deficiency in aging male patients with benign prostatic hyperplasia. Urologiya = Urology 2015;1:79–82. (In Russ.)].
22. McKay D. Nutrients and botanicals for erectile dysfunction: examining the evidence. Altern Med Rev 2004;9(1):4–16.
23. McNicholas T., Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid 2011.
24. Nashivochnikova N.A., Krupin V.N., Selivanova S.A. Effektivnost' spematona pri muzhskom besplodii. Urologiya 2014;2:52–4. [Nashivochnikova N.A., Krupin V.N., Selivanova S.A. Efficacy of Spematon administered at male infertility. Urologiya = Urology 2014;2:52–4. (In Russ.)].
25. Pul'bere S.A., Avdoshin V.P. Kombinirovannaya terapiya bol'nykh ostrym prostatitom s primeneniem fitopreparata prostagut forte. Urologiya 2012;5:57–63. [Pulbere S.A., Avdoshin V.P. Combined therapy of patients with acute prostatitis with administration of herb medicinal product Prostagutt forte. Urologiya = Urology 2012;5:57–63. (In Russ.)].
26. Liflyandskiĭ V.G. Noveĭshaya entsiklopediya nezamenimykh veshchestv. SPb.: Neva, 2004. 384 s. [Liflyandsky V.G. The modern encyclopedia of essential nutrients. Saint Petersburg: Neva, 2004. 384 p. (In Russ.)].
27. Wilt T., Ishani A., Mac Donald R. et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;1.
28. Larré S., Camparo P., Comperat E. et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl 2012;14(3):499–504.
29. Allkanjari O., Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 2015;126:42–56.
30. Maznev N.I. Entsiklopediya lekarstvennykh rasteniĭ. 3-e izd., ispr. i dop. M.: Martin, 2004. 496 s. [Maznev N.I. Encyclopedia of drug plants. 3rd revised and enlarged edition. Moscow: Martin, 2004. 496 p. (In Russ.)].
31. Vinogradova T.A., Gazhëv B.N., Vinogradov V.M., Martynov V.K. Prakticheskaya fitoterapiya M.: OLMA-PRESS; SPb.: Neva, Valeri SPD, 1998. 640 s. [Vinogradova T.A., Gazhyov B.N., Vinogradov V.M., Martynov V.K. Practical herbal medicine Moscow: OLMA-PRESS; Saint Petersburg: Neva, Valeri SPD, 1998. 640 p. (In Russ.)].
32. Korsun V.F., Korsun E.V. Fitoterapiya: traditsii rossiĭskogo travnichestva. M.: Eksmo, 2010. 880 s. [Korsun V.F., Korsun E.V. Herbal Medicine: traditions of the russian herbal drugs. M: Eksmo, 2010. 880 p. (In Russ.)].
33. Jang D.J., Lee M.S., Shin B.C. et al. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol 2008;66(4):444–50.
34. Liflyandskiĭ V.G. Vitaminy i mineraly. M.: ZAO «OLMA Media Grupp», 2010. 640 s. [Liflyandsky V.G. Vitamins and minerals. Moscow: OLMA Media Group JSC, 2010. 640 p. (In Russ.)].
35. Encyclopedia of human nutrition. 2nd ed. B. Caballero, L. Allen, A. Prentice (eds.). Oxford, 2005. 2167 p.
36. Present knowledge in nutrition. 10th ed. J.W. Erdman Jr. , I.A. Macdonald, S.H. Zeisel (eds.). Ames (USA), Oxford (UK): International Life Sciences Institute, 2012. 1329 p.
37. Tutel'yan V.A., Vyalkov A.I., Razumov A.N. i dr. Nauchnye osnovy zdorovogo pitaniya. M.: Panorama, 2010. 816 s. [V.A. Tutelyan, A.I. Vyalkov, A.N. Razumov et al. Scientific basis of healthy meal. Moscow: Panorama, 2010. 816 p. (In Russ.)].
38. Gropper S.S., Smith J.L. Advanced nutrition and human metabolism, 6th ed. Wadsworth, 2013. 608 p.
39. Whitney E., Rolfes S.R. Understanding Nutrition. 13th ed. Wadsworth, 2013. 975 p.
40. Doklinicheskoe izuchenie ostroĭ i subkhronicheskoĭ toksichnosti biologicheski aktivnoĭ dobavki (BAD) k pishche «TestogenonTM», kapsuly, 0,5 g, proizvodstva OOO «VIS». Otchet FGBU «Institut toksikologii FMBA». Spb., 2012. 29 s. [Preclinical study of acute and subchronic toxicity of dietary supplement (DS) TestogenonTM, capsules, 0,5 g, manufactured by “VIS” LLC. Report of FSBI “Institute of Toxicology of Federal Medical and Biological Agency of Russia”. Saint Petersburg, 2012. 29 p. (In Russ.)].
41. Doklinicheskoe izuchenie spetsificheskoĭ farmakologicheskoĭ aktivnosti biologicheski aktivnoĭ dobavki (BAD) k pishche «TestogenonTM», kapsuly, 0,5 g, proizvodstva OOO «VIS». Otchet FGBU «Institut toksikologii FMBA». Spb., 2012. 15 s. [Preclinical study of specific pharmacological activity of dietary supplement (DS) TestogenonTM, capsules, 0,5 g, manufactured by “VIS” LLC. Report of FSBI “Institute of Toxicology of Federal Medical and Biological Agency of Russia”. Saint Petersburg, 2012. 15 p. (In Russ.)].
